Validation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ
No Preview Available
Download
Associated Records
File Licence
Editors
Date
2018-07-03
Source Title
British Journal of Cancer
Journal Title
Journal ISSN
Volume Title
Publisher
NATURE PUBLISHING GROUP
Melbourne Authors
Affiliation
Sir Peter MacCallum Department of Oncology
Melbourne School of Population and Global Health
Melbourne School of Population and Global Health
Document Type
Journal Article
Subject Code
Citation
Lo, L. L., Milne, R. L., Liao, Y., Cuzick, J., Terry, M. B. & Phillips, K. A. (2018). Validation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ. British Journal of Cancer, 119 (1), pp.36-39. https://doi.org/10.1038/s41416-018-0120-z.
Access Status
Open Access
Access URL
Open Access URL
Open Access at PMC
Linked Resource URL
NHMRC Grant Code
ARC Grant Code
Description
Abstract
BACKGROUND: Management advice for women with lobular carcinoma in situ (LCIS) is hampered by the lack of accurate personalised risk estimates for subsequent invasive breast cancer (BC). Prospective validation of the only tool that estimates individual BC risk for a woman with LCIS, the International Breast Cancer Intervention Study Risk Evaluation Tool (IBIS-RET), is lacking. METHODS: Using population-based cancer registry data for 732 women with LCIS, the calibration and discrimination accuracy of IBIS-RET Version 7.2 were assessed. RESULTS: The mean observed 10-year risk of invasive BC was 14.1% (95% CI:11.3%-17.5%). IBIS-RET overestimated invasive BC risk (pā=ā0.0003) and demonstrated poor discriminatory accuracy (AUC 0.54, 95% CI: 0.48 - 0.62). CONCLUSIONS: Clinicians should understand that IBIS-RET Version 7.2 may overestimate 10-year invasive BC risk for Australian women with LCIS. The newer IBIS-RET Version 8.0, released September 2017, includes mammographic density and may perform better, but validation is needed.